scientif
commun
focuss
develop
antivir
therapi
mitig
impact
ongo
novel
coronaviru
diseas
facilit
improv
understand
viral
dynam
within
infect
host
use
mathemat
model
combin
publish
viral
load
data
collect
specimen
throat
nasal
swab
nasopharyng
sputum
tracheal
aspir
compar
withinhost
dynam
patient
infect
current
outbreak
analog
dynam
merscov
sarscov
infect
quantit
analys
reveal
infect
dynam
sever
mild
case
merscov
similar
sever
case
viral
dynam
sarscov
infect
similar
merscov
mild
case
sever
case
consequ
gener
infect
dynam
sever
sarscov
furthermor
use
viral
dynam
model
predict
effect
unlicens
drug
differ
method
action
effect
measur
auc
viral
load
result
indic
therapi
block
de
novo
infect
viru
product
like
effect
initi
peak
viral
load
occur
around
three
day
symptom
onset
averag
therapi
promot
cytotox
like
limit
effect
uniqu
mathemat
approach
provid
insight
pathogenesi
human
use
develop
antivir
therapi
keyword
merscov
sarscov
mathemat
model
antivir
therapi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
analys
data
describ
viral
load
report
zou
et
al
merscov
viral
load
report
oh
et
al
use
simpl
mathemat
model
see
method
consid
interindividu
variat
viral
load
nonlinear
mixedeffect
model
approach
employ
estim
paramet
see
method
estim
paramet
initi
valu
list
tabl
typic
behaviour
model
use
bestfit
paramet
estim
shown
togeth
data
fig
pink
merscov
black
grey
sever
mild
case
respect
addit
parameteris
compar
coronavirus
infect
calcul
follow
import
quantiti
fig
use
estim
paramet
valu
mean
length
viru
product
infect
cell
withinhost
basic
reproduct
number
averag
number
newli
infect
cell
produc
singl
infect
cell
critic
inhibit
rate
induc
antivir
prevent
primari
viru
infect
show
significantli
differ
merscov
howev
interestingli
found
significantli
differ
analog
valu
mild
case
merscov
bootstrap
ttest
respect
sever
merscov
see
fig
although
unabl
separ
mild
sever
case
due
limit
clinic
inform
case
demonstr
caus
infect
effect
mild
case
merscov
gener
infect
follow
infect
dynam
similar
sever
case
due
merscov
addit
median
estim
inhibit
initi
viru
expans
requir
prevent
establish
infect
provid
detail
analysi
later
also
calcul
durat
infect
viral
load
detect
limit
tabl
show
maintain
host
week
base
median
estim
extend
analysi
includ
sarscov
analys
sarscov
viral
load
nasopharyng
aspir
report
peiri
et
al
merscov
viral
load
report
oh
et
al
sputum
tracheal
aspir
estim
paramet
viral
load
symptom
onset
indic
deriv
estim
paramet
list
tabl
bootstrap
ttest
fig
demonstr
vivo
viral
dynam
sarscov
infect
similar
merscov
mild
case
sever
case
collect
find
viral
load
data
analys
two
differ
specimen
throatnas
swab
nasopharyngealsputumtrach
aspir
impli
also
caus
infect
effect
quantit
analys
provid
insight
optim
usag
fig
one
major
mechan
action
antivir
block
de
novo
infect
induc
drug
includ
human
neutralis
antibodi
viral
entryinhibitor
andor
antibodi
rais
vaccin
exampl
sarscovspecif
human
monoclon
antibodi
report
cross
react
conduct
silico
experi
vari
drug
efficaci
consid
inhibit
rate
ie
time
initi
therapi
day
ie
postexposur
prophylact
use
antivir
day
symptom
onset
ie
see
method
result
show
earli
initi
therapi
especi
within
two
three
day
even
rel
weak
drug
inhibit
rate
low
might
effect
reduc
area
curv
viral
load
auc
prevent
signific
reduct
number
target
cell
cytopath
effect
due
cell
invas
therapi
type
initi
four
day
symptom
onset
hand
predict
induc
clear
antivir
effect
fig
suggest
block
de
novo
infect
like
effect
unless
intervent
initi
peak
viral
load
henc
appropri
initi
time
ie
soon
symptom
onset
import
factor
suppress
viral
load
addit
therapi
potenti
antivir
effect
major
antivir
drug
inhibit
intracellular
viru
replic
although
antivir
efficaci
need
confirm
lopinavirritonavir
hiv
proteas
inhibitor
remdesivir
antiebola
viru
diseas
candid
nucleosid
analogu
interferon
potenti
suppress
block
viru
product
interestingli
result
suggest
even
rel
small
inhibit
rate
around
auc
viral
load
partial
reduc
therapi
initi
earli
within
three
day
symptom
onset
fig
howev
treatment
appli
peak
viral
load
even
drug
inhibit
rate
abl
reduc
viral
load
similar
predict
outcom
de
novo
block
therapi
iii
promot
cytotox
anoth
possibl
antivir
mechan
cytotox
effect
adapt
immun
includ
mediat
cytotox
lymphocyt
assum
promot
cytotox
increas
viru
death
rate
two
time
ie
achiev
reduct
mean
length
viru
product
compar
two
therapi
block
de
novo
infect
viru
product
induct
cytotox
rel
mild
effect
auc
reduct
initi
peak
viral
load
howev
cytotox
induct
initi
peak
viral
load
could
effect
reduc
viral
load
auc
fig
impli
optim
time
appli
therapi
signific
antivir
effect
expect
unless
promot
rate
low
therapi
initi
either
earli
late
howev
larg
reduct
target
cell
due
ongo
de
novo
infect
avoid
even
earli
initi
ie
immedi
symptom
onset
therapi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
number
potenti
transmiss
rout
includ
direct
persontoperson
transmiss
due
viral
particl
inhal
contact
transmiss
due
contact
nasaloraley
mucuou
membran
viru
product
effect
reduc
auc
load
exampl
therapi
reduc
de
novo
infect
initi
day
symptom
onset
viral
load
auc
expect
reduc
fig
howev
therapi
initi
peak
viral
load
day
follow
symptom
onset
effect
viral
load
auc
limit
compar
either
block
de
novo
infect
viru
product
promot
cytotox
show
rel
mild
effect
auc
reduct
howev
initi
therapi
peak
viral
load
potenti
still
reduc
viral
load
auc
fig
effect
hypothet
drug
evalu
detail
use
report
number
anim
model
exist
sarscov
includ
mice
hamster
ferret
macaqu
anim
could
use
verifi
conclus
model
monitor
viral
load
anim
treat
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
differ
type
drug
differ
dose
differ
initi
time
viral
load
data
would
allow
investig
effect
drug
differ
action
mechan
would
inform
develop
appropri
treatment
strategi
ie
optim
dosetim
antivir
conclus
effect
treatment
infect
requir
appropri
choic
classspecif
drug
otherwis
antivir
alter
viral
load
significantli
wast
identif
viru
characterist
need
design
optim
treatment
ensur
limit
resourc
deploy
effect
addit
effect
combin
drug
vaccin
maximis
impact
control
reduc
requir
drug
dose
potenti
limit
side
effect
highli
desir
theoret
approach
could
complement
ongo
experiment
investig
treatment
knowledg
previou
studi
neither
characteris
dynam
human
use
viral
dynam
model
compar
result
dynam
coronavirus
ie
sarscov
merscov
mathemat
model
approach
led
improv
understand
characterist
vivo
use
test
possibl
treatment
go
forward
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
examin
manuscript
came
studi
merscov
sarscov
zou
et
al
oh
et
al
peiri
et
al
respect
extract
data
imag
public
use
program
datathief
iii
version
ba
tummer
wwwdatathieforg
exclud
patient
data
measur
one
day
assum
viral
load
valu
detect
limit
set
detect
limit
purpos
fit
model
convert
cycl
threshold
ct
valu
report
zou
et
al
oh
et
al
peiri
et
al
viral
rna
copi
number
valu
quantiti
invers
proport
parameteris
coronaviru
infect
dynam
patient
viral
load
data
deriv
simplifi
mathemat
model
follow
viru
dynam
model
repres
rate
constant
viru
infect
death
rate
infect
cell
viral
product
rate
clearanc
rate
viru
respect
sinc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
clearanc
rate
viru
typic
much
larger
death
rate
infect
cell
vivo
made
quasisteadi
state
qss
assumpt
replac
eq
data
number
coronaviru
rna
copi
rather
number
infect
cell
avail
substitut
eq
obtain
furthermor
defin
ratio
number
uninfect
target
cell
time
initi
number
uninfect
target
cell
accordingli
obtain
follow
simplifi
mathemat
model
employ
analys
data
studi
cov
fit
use
nonlinear
mixedeffect
model
approach
describ
use
whole
sampl
estim
popul
paramet
also
account
interindividu
variat
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
utilis
novel
mathemat
model
estim
paramet
valu
investig
antivir
effect
unlicens
develop
promis
drug
follow
differ
mechan
action
depend
inhibit
rate
time
therapi
initi
block
de
novo
infect
eg
via
human
neutralis
antibodi
viral
entryinhibitor
antibodi
level
rais
vaccin
ii
block
viru
product
lopinavirritonavir
hiv
proteas
inhibitor
remdesivir
antiebola
viru
candid
nucleosid
analogu
interferon
therapi
median
paramet
set
use
predict
expect
outcom
therapi
word
even
though
drug
administr
trial
conduct
yet
abl
infer
efficaci
drug
treatment
base
silico
experi
implement
differ
mechan
action
model
follow
block
de
novo
infect
antivir
effect
block
de
novo
infect
therapi
impli
de
novo
infect
inhibit
initi
day
symptom
onset
model
assum
heavisid
step
function
defin
otherwis
evalu
expect
antivir
effect
therapi
differ
inhibit
rate
initi
time
use
estim
paramet
valu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
mean
reduct
cumul
viru
product
ie
area
curv
likelihood
estim
procedur
paramet
nonlinear
mixedeffect
model
employ
fit
viral
load
data
nonlinear
mixedeffect
model
approach
allow
fix
effect
well
random
effect
describ
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
variabl
includ
random
effect
amount
partial
pool
data
individu
improv
estim
paramet
applic
across
popul
patient
use
approach
differ
viral
dynam
differ
patient
estim
explicitli
fulli
pool
data
would
bia
estim
toward
highli
sampl
patient
method
estim
paramet
estim
depend
individu
fix
effect
random
effect
assum
gaussian
distribut
mean
standard
deviat
popul
paramet
individu
paramet
estim
use
stochast
approxim
expectationmaximis
algorithm
empir
bay
method
respect
individu
estim
paramet
initi
valu
patient
summar
tabl
use
paramet
compar
test
use
bootstrap
ttest
due
small
sampl
size
viral
load
sputumtrach
aspir
merscov
assum
fix
effect
mild
sever
merscov
case
otherwis
process
exactli
describ
throat
swab
data
comput
base
estim
paramet
distribut
calcul
sever
quantiti
durat
viru
product
basic
reproduct
number
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
critic
inhibit
rate
also
calcul
period
viral
load
detect
limit
silico
simul
individu
estim
paramet
initi
viral
load
equal
detect
limit
ie
numer
experi
began
point
viru
becam
detect
distribut
estim
calcul
separ
sarscov
well
sever
mild
case
merscov
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
